Stock vs Stock Comparison

Johnson & Johnson vs Merck & Co., Inc.

JNJ wins the Tale of the Tape 6–2.

JNJ$222.89
MRK$115.65

🏆 Tale of the Tape

62
JNJMRK
28.5%Profitability (Net Margin)28.1%
26.1xValuation (P/E)33.4x
18.3%Efficiency (ROIC)16.3%
4/9Health (Piotroski F)4/9
4.0Safety (Altman Z)4.0
6.0%Growth (Rev YoY)1.3%
2.69Risk (Sharpe 1Y)1.43
1.44xBalance Sheet (D/E)1.60x
3.25%FCF Yield3.72%

Green = winner in each category. Higher is better except P/E (lower = cheaper).

Rolling Correlation

0.469
252-Day Correlation
0.447
126-Day Correlation

Moderately correlated — some diversification benefit from holding both.

Fundamentals

MetricJNJMRK
Market Cap$542.4B$293.2B
P/E Ratio26.1x33.4x
Forward P/E17.7x12.4x
P/B6.68x6.39x
Dividend Yield2.38%2.86%
Beta0.260.20

Quantitative Metrics

MetricJNJMRK
DCF Fair Value$134.24$96.93
DCF Upside-43.6%-19.3%
Piotroski F4/94/9
Altman Z3.974.04
Beneish M-2.27-2.27
FCF Yield3.25%3.72%
Net Debt/EBITDA0.5x1.1x
ROIC18.3%16.3%
WACC7.7%7.4%
ROIC – WACC10.5pp8.9pp
Gross Margin67.9%74.8%
Net Margin28.5%28.1%
Rev Growth YoY6.0%1.3%
Sharpe (1Y)2.691.43
Max Drawdown 3Y-16.0%
FCF Payout Ratio64%66%

JNJ Price

Loading chart...

MRK Price

Loading chart...

ETF Exposure

JNJ found in:

XLV10.42%
IYH10.14%
VHT8.84%
HDV6.84%
MTUM3.76%
DIA2.83%
MGV2.75%
DGRO2.64%
VIG2.49%
VYM2.30%
VTV2.16%
DGRW2.02%
SCHV2.02%
IWD1.94%
QUS1.81%
XPH1.74%
VONV1.69%
NOBL1.58%
VFMV1.42%
VFMO1.02%
SCHX0.96%
SPYG0.94%
SDY0.93%
VOO0.90%
SCHB0.90%
SPY0.87%
IVV0.85%
VONE0.84%
SPTM0.81%
VTI0.80%
SPYV0.79%
SPLG0.76%
ITOT0.75%
URTH0.70%
ACWI0.57%
VT0.49%
RSP0.21%
VFVA0.15%
ONEO0.05%

MRK found in:

XLV5.37%
IYH4.97%
VHT4.39%
SCHD4.24%
XPH1.82%
MOAT1.52%
DIA1.42%
MGV1.34%
QUS1.24%
VIG1.22%
DVY1.22%
VYM1.13%
VTV1.05%
SCHV1.04%
DGRW1.03%
SPYV1.00%
IWD0.98%
VONV0.83%
VFVA0.72%
ESGV0.60%
SCHX0.49%
SCHB0.46%
SPY0.45%
IVV0.45%
VOO0.44%
VFMO0.44%
SPTM0.42%
VONE0.41%
ITOT0.39%
VTI0.39%
SPLG0.37%
URTH0.36%
ACWI0.29%
VT0.24%
RSP0.22%
ONEO0.12%
VGK0.11%
SPDW0.06%
VSGX0.06%
CWI0.06%
VEA0.05%
VXUS0.04%
VEU0.04%

More Comparisons

Quant metrics computed from financial statements and 1,200+ trading days. Correlation is Pearson coefficient on daily log returns. Not investment advice.

JNJ vs MRK: Head-to-Head Analysis

Johnson & Johnson (JNJ) and Merck & Co., Inc. (MRK) represent two companies in the Healthcare sector. In our quantitative Tale of the Tape scoring, JNJ leads 6–2 across nine fundamental and risk metrics including profitability, valuation, capital efficiency, and financial health.

In terms of capital efficiency, JNJ generates a return on invested capital (ROIC) of 18.3% compared to MRK's 16.3%. This suggests JNJ is more effective at deploying capital to generate shareholder returns.

The 252-day rolling correlation between JNJ and MRK is 0.469, indicating moderate co-movement, with some diversification value from holding both in a portfolio context.

JNJ appears in 39 ETFs tracked by SecuritiesDB, while MRK appears in 43 ETFs. Investors holding broad-market ETFs may already have indirect exposure to both stocks.

Frequently Asked Questions

Which stock is the better investment, JNJ or MRK?

Our quantitative analysis compares JNJ and MRK across nine fundamental dimensions. JNJ wins the Tale of the Tape 6–2. However, stock selection depends on your individual risk tolerance, time horizon, and portfolio context. These metrics are computed from SEC filings and market data — they are not investment recommendations.

Are JNJ and MRK correlated?

The 252-day correlation between JNJ and MRK is 0.469. They show moderate correlation — partially diversifying.

How is the Tale of the Tape scored?

The Tale of the Tape compares both stocks across nine categories: profitability (net margin), valuation (P/E), efficiency (ROIC), health (Piotroski F-Score), safety (Altman Z-Score), growth (revenue YoY), risk (Sharpe ratio), leverage (debt-to-equity), and cash generation (FCF yield). The stock that wins more categories takes the overall score. Lower P/E and lower debt-to-equity count as wins.